Market Overview

New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix — Consolidated Revenues, Company Growth, and Expectations for 2018

Share:

NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), PTC Therapeutics, Inc. (NASDAQ:PTCT), Boot Barn Holdings, Inc. (NYSE:BOOT), Darling Ingredients Inc. (NYSE:DAR), and Endologix, Inc. (NASDAQ:ELGX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MTSI DOWNLOAD: http://Fundamental-Markets.com/register/?so=MTSI
ARWR DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARWR
PTCT DOWNLOAD: http://Fundamental-Markets.com/register/?so=PTCT
BOOT DOWNLOAD: http://Fundamental-Markets.com/register/?so=BOOT
DAR DOWNLOAD: http://Fundamental-Markets.com/register/?so=DAR
ELGX DOWNLOAD: http://Fundamental-Markets.com/register/?so=ELGX

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), PTC Therapeutics, Inc. (NASDAQ:PTCT), Boot Barn Holdings, Inc. (NYSE:BOOT), Darling Ingredients Inc. (NYSE:DAR), and Endologix, Inc. (NASDAQ:ELGX) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 24th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

MACOM TECHNOLOGY SOLUTIONS HOLDINGS, INC. (MTSI) REPORT OVERVIEW

MACOM Technology Solutions' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, MACOM Technology Solutions reported revenue of $137.87MM vs $194.56MM (down 29.13%) and basic earnings per share -$1.32 vs -$0.43. For the twelve months ended September 30th, 2017 vs September 30th, 2016, MACOM Technology Solutions reported revenue of $698.77MM vs $544.34MM (up 28.37%) and basic earnings per share -$2.79 vs $0.03. MACOM Technology Solutions is expected to report earnings on November 13th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $0.47 and is expected to report on November 13th, 2018.

To read the full MACOM Technology Solutions Holdings, Inc. (MTSI) report, download it here: http://Fundamental-Markets.com/register/?so=MTSI

-----------------------------------------

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) REPORT OVERVIEW

Arrowhead Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Arrowhead Pharmaceuticals reported revenue of $0.73MM vs $9.34MM (down 92.21%) and basic earnings per share -$0.18 vs -$0.07. For the twelve months ended September 30th, 2017 vs September 30th, 2016, Arrowhead Pharmaceuticals reported revenue of $31.41MM vs $0.16MM (up 19,740.62%) and basic earnings per share -$0.47 vs -$1.34. Arrowhead Pharmaceuticals is expected to report earnings on December 11th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.59 and is expected to report on December 11th, 2018.

To read the full Arrowhead Pharmaceuticals, Inc. (ARWR) report, download it here: http://Fundamental-Markets.com/register/?so=ARWR

-----------------------------------------

PTC THERAPEUTICS, INC. (PTCT) REPORT OVERVIEW

PTC Therapeutics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, PTC Therapeutics reported revenue of $68.74MM vs $47.96MM (up 43.33%) and basic earnings per share -$0.21 vs -$0.44. For the twelve months ended December 31st, 2017 vs December 31st, 2016, PTC Therapeutics reported revenue of $194.39MM vs $82.71MM (up 135.04%) and basic earnings per share -$2.02 vs -$4.17. PTC Therapeutics is expected to report earnings on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is $1.01 and is expected to report on March 5th, 2019.

To read the full PTC Therapeutics, Inc. (PTCT) report, download it here: http://Fundamental-Markets.com/register/?so=PTCT

-----------------------------------------

BOOT BARN HOLDINGS, INC. (BOOT) REPORT OVERVIEW

Boot Barn's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Boot Barn reported revenue of $161.98MM vs $139.38MM (up 16.22%) and basic earnings per share $0.24 vs $0.03 (up 700.00%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Boot Barn reported revenue of $677.95MM vs $629.82MM (up 7.64%) and basic earnings per share $1.08 vs $0.54 (up 100.00%). Boot Barn is expected to report earnings on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal year is $1.35 and is expected to report on May 21st, 2019.

To read the full Boot Barn Holdings, Inc. (BOOT) report, download it here: http://Fundamental-Markets.com/register/?so=BOOT

-----------------------------------------

DARLING INGREDIENTS INC. (DAR) REPORT OVERVIEW

Darling Ingredients' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Darling Ingredients reported revenue of $846.65MM vs $894.93MM (down 5.40%) and basic earnings per share -$0.18 vs $0.06. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Darling Ingredients reported revenue of $3,662.25MM vs $3,391.93MM (up 7.97%) and basic earnings per share $0.78 vs $0.62 (up 25.81%). Darling Ingredients is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.05. The estimated EPS forecast for the next fiscal year is $0.94 and is expected to report on February 26th, 2019.

To read the full Darling Ingredients Inc. (DAR) report, download it here: http://Fundamental-Markets.com/register/?so=DAR

-----------------------------------------

ENDOLOGIX, INC. (ELGX) REPORT OVERVIEW

Endologix's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Endologix reported revenue of $44.74MM vs $48.56MM (down 7.86%) and basic earnings per share -$0.28 vs -$0.20. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Endologix reported revenue of $181.16MM vs $192.93MM (down 6.10%) and basic earnings per share -$0.80 vs -$1.91. Endologix is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.63 and is expected to report on February 20th, 2019.

To read the full Endologix, Inc. (ELGX) report, download it here: http://Fundamental-Markets.com/register/?so=ELGX

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!